Radionuclides as conditioning before stem cell transplantation.
Targeted radiotherapy using either radiolabeled monoclonal antibodies or bone-seeking radiopharmaceuticals can potentially result in delivery of high radiation doses to tumor or bone marrow with less toxicity to normal organs. High-dose radioimmunotherapy has produced encouraging results in lymphoma and leukemia. The use of alternative radionuclides and new combinations of radioimmunotherapy with chemotherapy may improve patient outcomes. Comparative trials will be necessary to confirm an improved therapeutic benefit with this approach.
Jurcic
J G
JG
Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.
Scheinberg
D A
DA
D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016499:Radioimmunotherapy; D016896:Treatment Outcome